Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2023

Caitlin E. Cox

December 28, 2023

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Daily News

FDA Approves Paradise Renal Denervation System: What Comes Next?

Todd Neale

November 08, 2023

News Daily News

FDA Approves Colchicine for Decreasing CV Events

Caitlin E. Cox

June 20, 2023

News Daily News

Higher Annual TAVI Volumes Linked to Greater Use of Embolic Protection

L.A. McKeown

August 23, 2022

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2021

Caitlin E. Cox

December 29, 2021

News Daily News

FDA Approves Shockwave Intravascular Lithotripsy for Calcified Coronaries

Shelley Wood

February 16, 2021

News Features

Funding the Future: How Industry Support for CV Trials Could Evolve

Michael O'Riordan

December 17, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Advertisement

TCTMD’s Top 10 Most Popular Stories for December 2023

Top Endovascular News of 2023

FDA Approves Paradise Renal Denervation System: What Comes Next?

FDA Approves Colchicine for Decreasing CV Events

Higher Annual TAVI Volumes Linked to Greater Use of Embolic Protection

TCTMD’s Top 10 Most Popular Stories for December 2021

FDA Approves Shockwave Intravascular Lithotripsy for Calcified Coronaries

Funding the Future: How Industry Support for CV Trials Could Evolve

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

FDA Expands TAVR Indication to Low-Risk Patients

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content